DexCare’s $50 Million Series B Financing

Fenwick & West advised DexCare on the deal.

DexCare, a data-driven intelligence company focused on healthcare access, announced its $50 million Series B financing. The round was led by Transformation Capital and included participation from all existing investors, Kaiser Permanente, Providence Ventures, Mass General Brigham, Define Ventures, Frist Cressey Ventures and SpringRock Ventures.

DexCare will use the new funds to support and accelerate its growth with investments in product and technology innovation, customer experience and recruiting talent.

The Fenwick transaction team was led by corporate partner Michael Esquivel (Picture) and included counsel Khang Tran and associate Kevin Cergol.

Involved fees earner: Kevin Cergol – Fenwick & West LLP; Michael Esquivel – Fenwick & West LLP; Khang Tran – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: DexCare;

Martina Bellini

Author: Martina Bellini